Top

Published in:

01-09-2011 | Research

Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based Analysis

Authors: Adele Caldarella, Emanuele Crocetti, Simonetta Bianchi, Vania Vezzosi, Carmelo Urso, Mauro Biancalani, Marco Zappa

Published in: Pathology & Oncology Research | Issue 3/2011

Abstract

The aim of this study is to evaluate the prognostic values of some biological parameters in a population based series of female breast cancer patients. Through the Tuscan Cancer Registry all the invasive breast cancer cases diagnosed during the period 2004–2005 in the provinces of Florence and Prato, central Italy, were retrieved. Molecular subtypes were analyzed defined by immunohistochemical markers, by age, tumor size, lymph node status, histotype, grade of differentiation and proliferative marker. Out of 1487 patients 70.3% were luminal A subtype (ER/PR + HER2-), 15.6% luminal B (ER/PR + HER2+), 8.1% triple negative (ER/PR-HER2-), 6.0% HER2+ (ER/PR-HER2+); the 3 year survival rates were 93.3%, 89.5%, 86.3%, 82.7% respectively (p < 0.001). Analysis of survival by the Cox proportional hazards model showed an independent prognostic value of molecular classification. Our study revealed significant differences in clinicopathological characteristics among breast cancer molecular subtypes and confirmed their prognostic independent role.

Lund MJ, Butler EN, Hair BJ, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, O’Regan RM, Vertino PM, Eley JW (2010) Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes. Cancer 116(11):2549–2559PubMed

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Gerardts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef

Yang XR, Sherman ME, Rimm DL, Lissowska J, Birnton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomark Prev 16(83):439–443CrossRef

Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two porspective cohort studies of breast cancer survivors. Breast Cancer Res 11:R31. doi:10.1186/bcr2261 PubMedCrossRef

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. A population-based study from the California Cancer Registry. Cancer 109:1721–1728PubMedCrossRef

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCrossRef

Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21:S8–S15PubMedCrossRef

Fernandes CMR, Bevilacqua JLB, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM (2009) Coordianted of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 55:346–352PubMedCrossRef

Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A (2009) Breast cancer classification according to imunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based from the South of Switzerland. Ann Oncol 20:628–635PubMedCrossRef

10.

Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Labbok MH, Gerardts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Hearp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139PubMedCrossRef

11.

Millar EKA, Graham PH, O’Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Cpp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701–4708PubMedCrossRef

12.

Barghava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM (2010) Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer. doi:10.1002/CNCR.24876

13.

Cheang MC, Voduc D, Bajdik C (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRef

14.

Rakha EA, Reis-Filho JS, Ellis AO (2010) Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-0746-x

15.

Hammond MEH, Hayes DF, Dowsett M, Allred DG, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clincial Oncologt/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:E1–E16

16.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn H-J, Panel members (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329PubMedCrossRef

17.

De P, Smith BR, Leyland-Jones B (2010) Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol 28(28):4289–4292PubMedCrossRef

Title: Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based Analysis
Authors: Adele Caldarella
Emanuele Crocetti
Simonetta Bianchi
Vania Vezzosi
Carmelo Urso
Mauro Biancalani
Marco Zappa
Publication date: 01-09-2011
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9381-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors

Epstein-Barr Virus and Breast Cancer: Lack of Evidence for an Association in Iranian Women

Extracellular Matrix Metalloproteinase Inducer is a Negative Prognostic Factor of Pediatric Medulloblastoma

Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response

Increased Expression of Toll-like Receptors (TLR) 2, 4 and 5 in Gastric Dysplasia

Effects of Homeodomain Protein CDX2 Expression on the Proliferation and Migration of Lovo Colon Cancer Cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer